705 related articles for article (PubMed ID: 11566599)
1. Recent developments in adjuvants for vaccines against infectious diseases.
O'Hagan DT; MacKichan ML; Singh M
Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in vaccine delivery systems.
O'Hagan DT
Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in vaccine adjuvants.
Singh M; O'Hagan DT
Pharm Res; 2002 Jun; 19(6):715-28. PubMed ID: 12134940
[TBL] [Abstract][Full Text] [Related]
4. Advances in vaccine adjuvants for infectious diseases.
Singh M; Srivastava I
Curr HIV Res; 2003 Jul; 1(3):309-20. PubMed ID: 15046255
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in veterinary vaccine adjuvants.
Singh M; O'Hagan DT
Int J Parasitol; 2003 May; 33(5-6):469-78. PubMed ID: 12782048
[TBL] [Abstract][Full Text] [Related]
6. [Adjuvants--essential components of new generation vaccines].
Dzierzbicka K; Kołodziejczyk AM
Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
[TBL] [Abstract][Full Text] [Related]
7. Microparticles as vaccine adjuvants and delivery systems.
O'Hagan DT; Singh M
Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
[TBL] [Abstract][Full Text] [Related]
8. Advances in vaccine adjuvants.
Singh M; O'Hagan D
Nat Biotechnol; 1999 Nov; 17(11):1075-81. PubMed ID: 10545912
[TBL] [Abstract][Full Text] [Related]
9. Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
Jennings R; Simms JR; Heath AW
Dev Biol Stand; 1998; 92():19-28. PubMed ID: 9554256
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in leishmaniasis vaccine delivery systems.
Bhowmick S; Ali N
Expert Opin Drug Deliv; 2008 Jul; 5(7):789-803. PubMed ID: 18590463
[TBL] [Abstract][Full Text] [Related]
11. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
12. An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines.
Garcia A; Lema D
Curr Pharm Des; 2016; 22(41):6294-6299. PubMed ID: 27634183
[TBL] [Abstract][Full Text] [Related]
13. An overview of adjuvant formulations and delivery systems.
García A; De Sanctis JB
APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
[TBL] [Abstract][Full Text] [Related]
14. Bacterial ghosts as adjuvant particles.
Riedmann EM; Kyd JM; Cripps AW; Lubitz W
Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
[TBL] [Abstract][Full Text] [Related]
15. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in vaccine adjuvants for systemic and mucosal administration.
O'Hagan DT
J Pharm Pharmacol; 1998 Jan; 50(1):1-10. PubMed ID: 9504429
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines--challenges in delivery.
Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant formulations and delivery systems for DNA vaccines.
Sasaki S; Takeshita F; Xin KQ; Ishii N; Okuda K
Methods; 2003 Nov; 31(3):243-54. PubMed ID: 14511957
[TBL] [Abstract][Full Text] [Related]
20. Fully mobilizing host defense: building better vaccines.
Raychaudhuri S; Rock KL
Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
